Predictors of Survival of Patients with Cancer of Unknown Primary Site: A Retrospective Study from Two Institutions in Egypt

Nervana M. Hussien 1, Zeinab Elsayed 2, Dina R. Ibrahim 2, Fatma M. Eltabakh 1

1 Department of Clinical Oncology, Faculty of Medicine, Helwan University, Cairo, Egypt; 2 Department of Clinical Oncology, Faculty of Medicine, Ain Shams University, Cairo, Egypt

Abstract

Background: Identification of prognostic factors in patients with cancer of unknown primary (CUP) is important to optimize their management.

Aim: To study the clinicopathological characteristics of patients with CUP and to identify factors that influence their survival.

Methods: A retrospective review of the medical records of 102 patients who presented with CUP in two Egyptian cancer care facilities during six years from 2012 to 2017 inclusive.

Results: The median age of patients was 61 years (range: 40-96) and 63% were males. Well-/moderately-differentiated adenocarcinoma was the most common histopathological diagnosis (60%) followed by poorly-differentiated carcinoma (25%). The common sites of metastases were the liver (56%), lymph nodes (56%), lungs (44%), and bones (38%). The initial treatment plan was single modality treatment in 43% of patients, combined modality in 16%, and best supportive care in 41%. The 6-month time-to-progression (TTP) and overall survival (OS) rates were 52.7% and 56.1%, respectively. Eastern Cooperative Oncology Group (ECOG) performance status >1, bone metastasis, low serum albumin, elevated serum alkaline phosphatase, and single agent chemotherapy treatment (compared to combination chemotherapy) were associated with significantly shorter TTP. Age ≥65 years, ECOG performance status >1, comorbidities, >1 metastatic site, bone metastasis, low serum albumin, elevated serum alkaline phosphatase, best supportive care / single modality treatment plan and single agent chemotherapy treatment (compared to combination chemotherapy) were associated with significantly shorter OS.

Conclusions: Many factors may affect the prognosis of CUP patients, e.g., old age, poor performance status, and low serum albumin. Further studies including a larger sample size are needed to develop predictive models based on these factors in patients with CUP.

Keywords: Cancer of unknown primary, Egypt, Prognostic factors, Survival

Introduction

Cancer of unknown primary (CUP) site represents a challenging diagnostic dilemma for oncologists, in which the site of origin of metastatic tumors remains obscure, even after comprehensive investigations 1, 2. Cancer of unknown primary constitutes approximately 3%-5% of all cancers 1. The biology of these tumors is unclear; however, current evidence suggests that metastatic dissemination can occur without primary tumor development due to cancer cells’ inherent metastatic aggressiveness 3. Chromosome instability has been proposed as part of the unusual clinical presentation and poor outcomes of CUP patients 4. The biological mechanisms behind this unusual clinical behavior are unknown and no identifiable molecular markers have been connected to these malignancies 5. As a
result, individuals with CUP are diagnosed only after performing specific clinical and histopathological investigations \(^4\), including histologic examination and immunohistochemistry (IHC) staining \(^6\).

The treatment of CUP patients begins with identifying favorable subgroups (20%) of individuals with particular clinical and/or pathologic manifestations \(^6\). The current guidelines detailed that favorable subgroups include female gender, young patients, isolated adenopathy, well-differentiated adenocarcinoma and squamous cell carcinoma, single metastatic site, and good performance status \(^8\). These individuals react rather well to specific treatments, and some have possibly curable malignancies \(^9\). Unfavorable subsets (80\%) of CUP patients typically receive platinum-based chemotherapy, an empiric chemotherapy regimen designed to effectively treat a wide range of cancer types. However, response and survival of these subsets of patients are generally poor \(^10\).

When a likely primary tumor is detected, and the proper therapy is performed, the prognosis usually improves \(^11\). Ten to forty percent of CUP patients have metastasis in their lymph nodes, whereas the rest of the patients have metastases in their internal organs \(^12\). Even though the underlying tumor is frequently undetected, several clinicopathologic characteristics of CUP indicate groups of individuals with a better prognosis \(^13\). The prognosis is particularly good in CUP restricted to lymph nodes and with histology other than adenocarcinoma. On the contrary, liver metastasis and several organs, including the brain, lung/pleura, and bone, indicate a poor prognosis \(^6\). No immediate critical function compromise accounts for the good prognosis in individuals with lymph node metastases. However, survival rates differ depending on whether lymph nodes are involved \(^14\).

This study aimed to identify the prognostic factors that influence the survival of Egyptian patients with CUP.

**Methods**

**Study design, setting, and participants**

This was a retrospective study, which was performed to collect data from the medical records of all patients presenting with CUP from January 2012 to December 2017 at two Egyptian cancer care centers, the Clinical Oncology Departments of Ain Shams and Helwan Universities in Cairo. Only patients aged ≥18 years with an established CUP diagnosis, as suggested by pathological, radiological, and IHC examination were included. We excluded patients who were hospitalized with life-threatening comorbidities, patients with brain metastasis, and patients whose records did not include survival data. Initially, records of 150 CUP patients were retrieved; the primary sites were identified in 48 (32\%) patients and were excluded, while the remaining 102 patients fulfilled the inclusion criteria and were recruited retrospectively.

**Data collection and study’s outcomes**

The following data were collected: age, gender, Eastern Cooperative Oncology Group (ECOG) performance status, comorbidity, pathological findings, tumor grade, IHC findings, number of affected organs, sites, type of obtained biopsy, diagnostic tools performed as the type of performed endoscopy, type of performed imaging, laboratory findings including serum tumor markers, treatment modalities planned. Response to treatment (RTT) was assessed according to the revised RECIST 1.1 \(^15\).

The primary outcome of the present study was to explore the frequencies and distribution of clinical characteristics and to define the correlations and dependencies.

The secondary outcomes were to investigate the factors significantly affecting time-to-progression (TTP) and overall survival (OS) among patients with CUP.

**Statistical analysis**

Data analysis was conducted using IBM SPSS Statistics for Windows, Version 20.0 (Armonk, NY: IMB Corp.). Quantitative data were described in terms of mean ± standard deviation (±SD), while qualitative data were expressed as frequencies and percentages. Time-to-progression was defined as the time from the date of diagnosis and the date of disease progression and OS as the time from diagnosis until death. The Kaplan-Meier method was used for TTP and OS analysis. The association between various patients’ characteristics and TTP / OS was tested using the log-rank test. A p value <0.05 was considered significant.

**Reporting guidelines**

We followed the STROBE statement recommendations during the preparation of this report \(^16\).
Results

Characteristics of the included patients and a summary of investigations done in the search for primary cancer are shown in Table 1. The median age of patients was 61 years (range: 40-96) and the majority had performance status >1 (65.6%), and more than half of the patients had comorbidities. The pathological examination revealed that well- /moderately-differentiated adenocarcinoma is the most common pathology and nearly two-thirds of the patients had grade II tumors. CK20 and CK7 were studied in all patients. Thirty-three (32.4%) patients were CK20 -ve CK7 +ve, 36 (35.3%) CK20 +ve CK7 -ve and 30 (29.4%) CK20 +ve CK7 +ve. Carcinoembryonic antigen, CA15.3, and CA125 were elevated in 22.6%, 15.8%, and 28.9% of selected patients.

Table 1: Characteristics of 102 patients with cancer of unknown primary and summary of investigations (continued)

| Characteristic / Investigation | n (%) |
|------------------------------|-------|
| Liver                        | 57 (55.9) |
| Lymph nodes                  | 57 (55.9) |
| Lung                         | 45 (44.1) |
| Bone                         | 39 (38.2) |
| Others                       | 38 (37.3) |

| Biopsy                        |       |
|-------------------------------|-------|
| Core needle                   | 48 (47.1) |
| Fine needle aspiration cytology | 28 (27.5) |
| Excisional                    | 26 (25.5) |

| Endoscopy                     |       |
|-------------------------------|-------|
| Upper gastrointestinal        | 11 (10.8) |
| Bronchoscopy with BAL         | 9 (8.8) |
| Lower gastrointestinal        | 1 (1) |
| None                          | 81 (79.4) |

| Imaging                       |       |
|-------------------------------|-------|
| Computerized tomography       | 60 (58.8) |
| Positron emission tomography  | 7 (6.9) |
| Combined                      | 35 (34.3) |

| Elevated lactate dehydrogenase | 20 / 62 (32.3) |
|                                  |               |
| Low serum albumin               | 23 / 62 (37.1) |
| Elevated alkaline phosphatase   | 26 / 62 (41.9) |

| Tumor Markers                  |       |
|-------------------------------|-------|
| Elevated CEA                  | 14 / 62 (22.6) |
| Elevated CA15.3               | 6 / 38 (15.8) |
| Elevated CA125                | 11 / 38 (28.9) |

ECOG: Eastern Cooperative Oncology Group, CEA: Carcinoembryonic antigen; BAL: Bronchoalveolar lavage

The treatment modalities and response to treatment are illustrated in Table 2. Twenty-one (20.6%) patients underwent surgery, mainly in the form of excisional biopsy. On the other hand, 44 (43.1%) patients received chemotherapy alone as a single agent in 10 (22.7%) and combined regimens in 34 (77.3%) patients.

The estimated mean TTP was 5 months (95%CI: 4.3-5.6) and the median was not reached. The 6-month TTP rate for the whole group of patients was 52.7%. Eastern Cooperative Oncology Group performance status >1, bone metastasis, low serum albumin, elevated serum alkaline phosphatase as well as the administration of single agent chemotherapy were associated with significantly shorter TTP (Table 3).

The estimated mean OS was 8.6 months (95%CI: 7.7-9.6) and the median was 8 (95%CI: 6-10). The 6-month OS rate for the whole group was 56.1%. Age ≥65 years, ECOG performance status >1, comorbidities, bone metastasis, low serum albumin,
Table 2: Treatment modalities and response

| Treatment plan                          | n (%)     |
|----------------------------------------|-----------|
| Best Supportive Care from the start     | 42 (41.2) |
| Single modality treatment               | 44 (43.1) |
| Combined modality treatment             | 16 (15.7) |

**Surgery**

- Excisional biopsy: 14 (13.7)
- Debulking surgery: 7 (6.9)
- None: 81 (79.4)

**Type of Chemotherapy**

- Gemcitabine-based combination: 20 (19.6)
- Taxane-based combination: 14 (13.7)
- Gemcitabine single agent: 7 (6.9)
- Capecitabine single agent: 3 (2.9)
- None: 58 (56.9)

**Response to treatment***

- Complete Response: 5 (4.9)
- Partial Response: 20 (19.6)
- Stationary course: 30 (29.4)
- Progression: 47 (46.1)

*Including patients who received best supportive care only

*showed that old age, poor performance status, presence of comorbidity, and elevated laboratory parameters significantly predict poor survival in patients with CUP. On the other hand, combined chemotherapy regimens and combined treatment modalities significantly predict favorable survival.

Our findings agreed with Fernandez-Cotarelo et al. 19, who found that CUP has a poor prognosis with a median OS of 2.5 months. They also reported that the main predictors of better prognosis and longer OS were age (<70 years), one affected organ (one), squamous cell carcinoma, lymph node enlargement, normal serum tumor markers, and the early administration of treatment. On the other hand, they did not find any significant association between gender and bone and pulmonary involvement and the prognosis of CUP. Similarly, the study by Polyzoidis et al. showed that age (<65 years), number of tumors (single), performance status, method of therapy, and absence of comorbidities, were associated with better prognosis in patients with brain tumors of unknown primary origin 20. In the study of Hemminki et al. 7, they included around 19,000 patients with CUP. They demonstrated that more than 70% of the included patients had adenocarcinoma, with a median OS of 3 months. In addition, they found that patients with squamous cell carcinoma had a substantially better OS (103 months) compared to malignant melanoma (31 months) and adenocarcinoma (8 months). Their findings highlighted the importance of histology and location of the tumor as reliable predictors of OS. In a cohort of 100 patients with CUP, Lorenzo et al. developed a prognostic model based on the performance status and the liver involvement only 21. However, in the letter to the editor of Munoz and his colleagues, they showed that after applying this model to their patients, they found that these two factors alone were not sufficient to predict the survival of patients with CUP, as the model failed to discriminate between the intermediate and poor prognostic groups. In addition, they concluded that this model alone could not be used in detecting the treatment approach of patients with CUP 22. Therefore, the application of well-designed models is recommended to avoid false indications.

**Discussion**

Generally, individuals with CUP tend to have a poor prognosis, with a median survival of 2–9 months 17. Nevertheless, certain groups have a better prognosis and survive better. Prognostic and predictive variables in CUP have been investigated, including age, gender, performance status, weight loss, histology, tumor size, tumor location, number of metastatic locations, and serum markers 11. Several prognostic and predictive variables, both positive and negative, were discovered, contributing to CUP patients' classification into favorable and unfavorable categories 18. In addition, specific histological subsets, lymph node involvement, number of metastatic sites, gender, performance status, weight loss, and some serum tumor markers have been identified as significant factors, and this is not consistent across studies.

This retrospective cohort study showed that the 6-month PFS and OS rates of CUP patients were 52.7% and 56.1%, respectively. In addition, the study showed that elevated serum alkaline phosphatase, best supportive care / single modality treatment plan, administration of single agent chemotherapy regimen, and progression in response to treatment were associated with significantly shorter OS (Table 3).
Table 3: The relation between the studied variables and time-to-progression and overall survival

| Variable                        | n  | Time-to-progression | Overall survival |
|---------------------------------|----|---------------------|-----------------|
|                                 |    | 6-month rate | SE | p value* | 6-month rate | SE | p value* |
| **Age (years)**                 |    |              |     |          |              |     |          |
| < 65                            | 68 | 54.9 %        | 7  | 0.24     | 63.6 %       | 6  | 0.005    |
| ≥ 65                            | 34 | 50.2 %        | 9  |          | 41.2 %       | 8  |          |
| **Gender**                      |    |              |     |          |              |     |          |
| Male                            | 64 | 47.6 %        | 6  | 0.075    | 48.3 %       | 6  | 0.072    |
| Female                          | 38 | 61.5 %        | 11 |          | 68.4 %       | 7  |          |
| **ECOG performance status**     |    |              |     |          |              |     |          |
| 1                               | 35 | 77.3 %        | 8  | <0.0001  | 88.2 %       | 5  | <0.001   |
| 2                               | 40 | 55 %          | 8  |          | 56.7 %       | 7  |          |
| 3                               | 19 | 21.1 %        | 9  |          | 17.8 %       | 9  |          |
| 4                               | 8  | 18.8 %        | 17 |          | 0 %          | 0  |          |
| **Comorbidities**               |    |              |     |          |              |     |          |
| No                              | 45 | 59.8 %        | 8  | 0.117    | 74.7 %       | 6  | 0.029    |
| Yes                             | 57 | 49.1 %        | 7  |          | 41.7 %       | 6  |          |
| **Pathology**                   |    |              |     |          |              |     |          |
| Well-/ moderately-differentiated adenocarcinoma | 61 | 59 %      | 6  | 0.552    | 54.7 %       | 7  | 0.193    |
| Poorly differentiated carcinoma  | 25 | 45.7 %        | 11 |          | 60 %         | 10 |          |
| Other                           | 16 | 50 %          | 13 |          | 56.3 %       | 12 |          |
| **Number of affected sites**    |    |              |     |          |              |     |          |
| 1                               | 12 | 64.3 %        | 15 | 0.189    | 90.9 %       | 8  | 0.007    |
| 2                               | 55 | 59.3 %        | 7  |          | 54.5 %       | 6  |          |
| ≥3                              | 35 | 44.2 %        | 9  |          | 47.1 %       | 8  |          |
| **Bone metastasis**             |    |              |     |          |              |     |          |
| No                              | 63 | 59 %          | 7  | 0.03     | 64.5 %       | 6  | 0.028    |
| Yes                             | 39 | 43.3 %        | 8  |          | 42.5 %       | 8  |          |
| **Liver metastasis**            |    |              |     |          |              |     |          |
| No                              | 45 | 52.1 %        | 8  | 0.876    | 61.6 %       | 7  | 0.433    |
| Yes                             | 57 | 55.4 %        | 7  |          | 51.8 %       | 6  |          |
| **L.N metastasis**              |    |              |     |          |              |     |          |
| No                              | 45 | 65.9 %        | 7  | 0.063    | 52.1 %       | 7  | 0.491    |
| Yes                             | 57 | 44.5 %        | 7  |          | 59.1 %       | 6  |          |
| **Pulmonary metastasis**        |    |              |     |          |              |     |          |
| No                              | 57 | 59.4 %        | 8  | 0.077    | 57.9 %       | 6  | 0.285    |
| Yes                             | 45 | 45.5 %        | 8  |          | 53.7 %       | 7  |          |
| **Other metastases**            |    |              |     |          |              |     |          |
| No                              | 64 | 45.5 %        | 7  | 0.135    | 61.6 %       | 6  | 0.12     |
| Yes                             | 38 | 63.8 %        | 8  |          | 46.9 %       | 8  |          |
| **Lactate dehydrogenase**       |    |              |     |          |              |     |          |
| Normal                          | 42 | 54.8 %        | 8  | 0.683    | 53.5 %       | 7  | 0.78     |
| Elevated                        | 20 | 65 %          | 11 |          | 53.8 %       | 11 |          |
| **Serum albumin**               |    |              |     |          |              |     |          |
| Normal                          | 39 | 76.9 %        | 7  | <0.0001  | 63.6 %       | 7  | <0.001   |
| Low                             | 23 | 26.1 %        | 9  |          | 37.1 %       | 10 |          |
| **Serum alkaline phosphatase**  |    |              |     |          |              |     |          |
| Normal                          | 36 | 77.8 %        | 7  | 0.0002   | 62.5 %       | 8  | 0.022    |
| Elevated                        | 26 | 30.8 %        | 9  |          | 41.1 %       | 9  |          |
| **Carcinoembryonic antigen**    |    |              |     |          |              |     |          |
| Normal                          | 48 | 62.5 %        | 7  | 0.09     | 51.7 %       | 7  | 0.947    |
| Elevated                        | 14 | 42.9 %        | 13 |          | 62.5 %       | 13 |          |
| **CA15.3**                      |    |              |     |          |              |     |          |
| Normal                          | 32 | 60.9 %        | 12 | 0.983    | 68.8 %       | 8  | 0.7      |
| Elevated                        | 6  | 66.7 %        | 19 |          | 66.7 %       | 19 |          |
| **CA125**                       |    |              |     |          |              |     |          |
| Normal                          | 27 | 55.5 %        | 14 | 0.629    | 74.1 %       | 8  | 0.7      |
| Elevated                        | 11 | 72.7 %        | 13 |          | 54.4 %       | 15 |          |
| **Treatment regimen**           |    |              |     |          |              |     |          |
| Best supportive care            | 42 | 60.2 %        | 8  | 0.617    | 47 %         | 7  | 0.008    |
| Single modality                 | 44 | 47 %          | 8  |          | 53 %         | 7  |          |
| Combined modality               | 16 | 56.3 %        | 12 |          | 87.5 %       | 8  |          |
| **Type of chemotherapy**        |    |              |     |          |              |     |          |
| Single agent chemotherapy       | 10 | 20 %          | 13 | 0.004    | 0 %          | 0  | <0.001   |
| Combination chemotherapy        | 34 | 64.7 %        | 8  |          | 70.2 %       | 7  |          |
| **Treatment response**          |    |              |     |          |              |     |          |
| Complete / partial response     | 25 | 88 %          | 6  | <0.001   |              |     |          |
| Stationary                      | 30 | 66.2 %        | 8  |          |              |     |          |
| Progression                     | 47 | 31.6 %        | 7  |          |              |     |          |

*Log-rank test, ECOG: Eastern Cooperative Oncology Group
According to the Egyptian study published by El-Shebiney and Maria on 84 patients with CUP, there are many prognostic factors for CUP, including performance status, histopathological subtypes, liver metastasis, lung metastasis, brain metastasis, albumin level, and the number of metastasis locations. However, the authors developed a simple model based on the performance status and the number of metastasis locations. The utilization of these two factors was based on multivariate analysis. The model classified the patients into two groups: poor-risk and good-risk. They found a significant difference between both groups in terms of one-year survival (p<0.0001) 23. Poor PS was also found to be an unfavorable prognostic factor in the studies of Culiné et al. 24 and Seve et al. 25. Several studies have found that when it comes to the number of organs involved by metastases, CUP patients with a single involved organ had a better survival time compared to individuals with two or more involved organs 21, 26. However, Abbruzzese et al. 12 and Grau et al. 27 found that CUP patients with three or more organs involved by the tumor did not have a worse prognosis.

In a series of 311 patients, Petrakis et al. demonstrated that the median of OS and PFS was 8 and 4 months, respectively 28. They developed an algorithm that predicts the OS of CUP patients up to 36 months, using three parameters; performance status, white blood cell count, and the clinicopathologic subgroup. If the patient has a tumor within serous peritoneal or axillary nodal, they classified him as low risk with a median OS of 36 months, without any further investigations. However, if the patient has a visceral subtype with elevated white blood cell count (>10,000/mm3) and worse performance status, he will be classified as high-risk, and the median of OS will be five months. We believe that this algorithm needs a larger sample to be validated.

To our knowledge, few studies investigated the predictors of survival among CUP patients from the Middle East. Nonetheless, we acknowledge that the present study has some limitations. The baseline data of the included patients were collected retrospectively, which prone the study to increased risk of misclassification and recording bias. Besides, there were no available data concerning the findings of various diagnostic modalities to correlate them with patients’ survival.

Conclusions
In conclusion, the current study confirms the poor prognosis of CUP. Older age, poorer performance status (>1), >1 affected organ, presence of comorbidities, lower albumin level, elevated alkaline phosphatase level and bony metastasis are predictors of worse prognosis in CUP patients. On the other hand, the response to treatment is associated with favorable survival. Further studies with larger sample size are required to assess the role of these factors in predicting the prognosis of patients with CUP.

Acknowledgments
Not applicable

Authors’ contribution
Conception or design: NMH; Acquisition, analysis, or interpretation of data: NMH, FME; Drafting the manuscript: NMH; Revising the manuscript: ZMA, DR, FME; Approval of the manuscript version to be published: All authors; Agreement to be accountable for all aspects of the work: All authors.

Conflict of interest
The authors declare that they have no conflict of interest to disclose.

Data availability
Deidentified individual participant data used to produce the results of this study are available from the corresponding author (NMH) on request.

Ethical considerations
Not applicable.

Funding
Not applicable.

Study registration
Not applicable.

References
1 Pavlidis N, Pentheroudakis G. Cancer of unknown primary site. Lancet. 2012; 379(9824): 1428-1435.
2 Søndergaard D, Nielsen S, Pedersen CNS, Besenbacher S. Prediction of primary tumors in cancers of unknown primary. J Integr Bioinform. 2017; 14(2): 20170013.
3 Haratani K, Hayashi H, Takahama T, et al. Clinical and immune profiling for cancer of unknown primary site. J Immunother cancer. 2019; 7(1): 251.
4 Hainsworth JD, Greco FA. Cancer of unknown primary site: new treatment paradigms in the era of precision medicine. Am Soc Clin Oncol Educ Book. 2018; (38): 20-25.
5 Hainsworth JD, Greco FA. Cancer of unknown primary site. In: The American Cancer Society’s Oncology in Practice: Clinical Management. Hoboken, NJ: Wiley, 2018, pp: 645-660.
6 Fizazi K, Greco FA, Pavlidis N, et al. Cancers of
unknown primary site: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2015; 26(Suppl 5): v133-v138.

7 Hemminki K, Bevier M, Hemminki A, Sundquist J. Survival in cancer of unknown primary site: Population-based analysis by site and histology. Ann Oncol. 2012; 23(7): 1854-1863.

8 Losa F, Soler G, Casado A, et al. SEOM clinical guideline on unknown primary cancer (2017). Clin Transl Oncol. 2018; 20(1): 89-96.

9 Collado Martín R, García Palomo A, de la Cruz Merino L, Borrega García P, Barón Duarte FJ. Spanish Society for Medical Oncology. Clinical guideline SEOM: cancer of unknown primary site. Clin Transl Oncol. 2014; 16(12): 1091-1097.

10 Møller AKH, Pedersen KD, Gothelf A, Daugaard G. Paclitaxel, cisplatin and gemcitabine in treatment of carcinomas of unknown primary site, a phase II study. Acta Oncol. 2010; 49(4): 423-430.

11 Abbruzzese JL, Abbruzzese MC, Lenzi R, Hess KR, Raber MN. Analysis of a diagnostic strategy for patients with suspected tumors of unknown origin. J Clin Oncol. 1995; 13(8): 2094-2103.

12 Abbruzzese JL, Abbruzzese MC, Hess KR, Raber MN, Lenzi R, Frost P. Unknown primary carcinoma: Natural history and prognostic factors in 657 consecutive patients. J Clin Oncol. 1994; 12(6): 1272-1280.

13 Culine S. Prognostic factors in unknown primary cancer. Semin Oncol. 2009; 36(1): 60-64.

14 Sleeman JP, Nazarenko I, Thiele W. Do all roads lead to Rome? Routes to metastasis development. Int J Cancer. 2011; 128(11): 2511-2526.

15 Eisenhauer EA, Therasse P, Bogaerts J, et al. New response evaluation criteria in solid tumors.revised RECIST guideline (version 1.1). Eur J Cancer. 2009; 45(2): 228-247.

16 von Elm E, Altman DG, Egger M, et al. The strengthening the reporting of observational studies in epidemiology (STROBE) statement: Guidelines for reporting observational studies. Int J Surg. 2014; 12(12): 1495-1499.

17 Pavlidis N, Briassoulis E, Hainsworth J, Greco FA. Diagnostic and therapeutic management of cancer of an unknown primary. Eur J Cancer. 2003; 39(14): 1990-2005.

18 Pasterz R, Savaraj N, Burgess M. Prognostic factors in metastatic carcinoma of unknown primary. J Clin Oncol. 1986; 4(11): 1652-1657.

19 Fernandez-Cotarelo MJ, Guerra-Vales JM, Colina F, de la Cruz J. Prognostic factors in cancer of unknown primary site. Tumori. 2010; 96(1): 111-116.

20 Polyzoïdis KS, Miliaras G, Pavlidis N. Brain metastasis of unknown primary: a diagnostic and therapeutic dilemma. Cancer Treat Rev. 2005; 31(4): 247-255.

21 Ponce Lorenzo J, Segura Huerta A, Díaz Beveridge R, et al. Carcinoma of unknown primary site: Development in a single institution of a prognostic model based on clinical and serum variables. Clin Transl Oncol. 2007; 9(7): 452-458.

22 Muñoz A, Fuente N, Rubio I, Ferreiro J, Martínez-Bueno A, López-Vivanco G. Prognostic factors in cancer of unknown primary site. Clin Transl Oncol. 2008; 10(1): 65-65.

23 El-Shebiney M, Marla A. Performance status and the number of the metastatic sites are powerful prognostic factors in patients with carcinomas of unknown primary site. J Am Science. 2011; 7(10): 442-447.

24 Culine S, Kramar A, Saghatchian M, et al. Development and validation of a prognostic model to predict the length of survival in patients with carcinomas of an unknown primary site. J Clin Oncol. 2002; 20(24): 4679-4683.

25 Seve P, Sawyer M, Hanson J, Broussolle C, Dumontet C, Mackey JR. The influence of comorbidities, age, and performance status on the prognosis and treatment of patients with metastatic carcinomas of unknown primary site: a population-based study. Cancer. 2006; 106(9): 2058-2066.

26 Pimienta JM, Teso D, Malkan A, Dudrick SJ, Palesty JA. Cancer of unknown primary origin: a decade of experience in a community-based hospital. Am J Surg. 2007; 194(6): 833-838.

27 Grau C, Johansen LV, Jakobsen J, Geertsen P, Andersen E, Jensen BB. Cervical lymph node metastases from unknown primary tumours: Results from a national survey by the Danish Society for Head and Neck Oncology. Radiother Oncol. 2000; 55(2): 121-129.

28 Petrakis D, Pentheroudakis G, Voulgaris E, Pavlidis N. Prognostication in cancer of unknown primary ( CUP ): Development of a prognostic algorithm in 311 cases and review of the literature. Cancer Treat Rev. 2013; 39(7): 701-708.